Reata Pharmaceuticals Inc - Class A
RETA
$27.60
-76.7% last 12 months
$27.60
-76.7% last 12 months
$885 Million
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.$25.02 - $153.41
The lowest and highst price in the last 52 weeks.-3.19x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$0.00 (0.0%)
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).| Market Cap | $885 Million |
| Enterprise Value | $172 Million |
| Dividend Yield | $0.00 (0.0%) |
| 1 Year Return | -76.7% |
| 52-Week High | $153.41 |
| 52-Week Low | $25.02 |
| Beta | 0.0 |
| Outstanding Shares | 31.5 Million |
| Avg 30 Day Volume | 761 Thousand |
| P/E Ratio | -3.19 |
| PEG | -32.65 |
| Earnings per Share | -$7.74 |
| Price to Sales Ratio | Infinity |
| Price to Book Ratio | 3.45 |
| Revenue to Enterprise Value | 12.52 |
| EBIT to Enterprise Value | -0.76 |
| Total Debt to Enterprise Value | 0.0 |
| Debt to Equity | 0.0 |
| Revenue | $13.7 Million |
| Gross Profit | $13.7 Million |
| EBIT | -$227 Million |
| Net Income | -$278 Million |
| Profit Margin | -2020.49% |
| Quarterly Earnings Growth (YoY) | +9.8% |
| Return on Equity | -108.52% |
| Return on Assets | -37.96% |
| Return on Invested Capital | -37.2% |
No purchases
9,254 shares sold (2 transactions)
No purchases
No sells
16,000 shares bought (1 transactions)
No sells
No purchases
No sells
CEO: J. Warren Huff
Industry: Pharmaceutical Preparation Manufacturing
Morgan Stanley raised its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 9.9% in the second quarter, according to the company in its most recent filin...
MADDEN SECURITIES Corp lowered its holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 4.8% in the 3rd quarter, according to its most recent Form 13F fi...
Wall Street analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to announce ($2.58) earnings per share for the current quarter, according to Zacks Inve...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (Reata, the Company, our, us, or we), a clinical-stage biopharmaceutical company, today announced the U.S. Food a...
